Mission Statement
We are developing reproducible and scalable 2D and 3D Micro-Physiological System (MPS) models that recapitulate key features of human AD and ADRD pathophysiology. These platforms will be used as precision medicine research tools to investigate complex AD biology and to accelerate drug discovery and preclinical drug development.
Goals:
- Develop standardized and well characterized 2D and 3D MPS models of AD/ADRD
- Validity the ability of the models to recapitulate key translational features of AD/ADRD across molecular, biochemical, cellular and histological phenotypes
- Develop methods for rigorous preclinical efficacy and safety testing and identify readouts that can serve as biomarkers of target engagement, safety, and efficacy
- Ensure rapid and broad distribution of the models, data, and methods for use in basic research and therapeutic development
Contact Us:
External Advisory Board
Clive Svendsen
Professor and Executive Director
Cedars-Sinai Regenerative Medicine Institute
Sally Temple
Scientific Director
Neural Stem Cell Institute
Thomas K. Baker
Investigative Toxicology
Eli Lilly and Company
Peter Searson
Professor of Materials Science and Engineering
John Hopkins University
Celeste Karch
Professor of Psychiatry
Washington University School of Medicine
Lorenz Studer
Director, Center for Stem Cell Biology
Member, Developmental Biology Program
Memorial Sloan Kettering Cancer Center
Gil Di Paolo
Executive Director, Discovery Biology
Denali Therapeutics
Amantha Thathiah
Associate Professor of Neurobiology
University of Pittsburgh
Mark Schurdak
Associate Professor in Computational and Systems Biology
University of Pittsburgh
Susan Catalano
Chief Scientific Officer
CODA Biotherapeutics
Heather Snyder
Senior Vice President, Medical & Scientific Relations
Alzheimer’s Association
David (Chun-Ting) Lee
Pharmacology-Toxicology Reviewer (ON/CDER)
FDA